xMedica

NCT05125302ClinicalTrials.gov

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study…

Fase 31059 partecipanti ricercati129 centri2 paesi

Categorie

Neurologia94%Gastroenterologia ed epatologia6%

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Registered before enrolment beganFirst posted 2021-11-18; recorded start 2022-01-13
  • Has a defined primary outcomeA primary outcome measure is listed in the record
  • The primary outcome states a time frameThe primary outcome measure records a time frame
  • Participants are randomly assignedAllocation is recorded as randomised
  • Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Uses blinding (masking)A masking level is recorded in the record
  • An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Sponsor has 378 other studies in this databaseCounted from the lead sponsor named in the record (AbbVie)
  • Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding16/20

    Triple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 129 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 1,059 participants (target), run at 129 sites, across 2 countries.

How this score is built
  • Enrolment30/40

    1,059 participants (target)

  • Site count23/25

    129 sites

  • Country count7/15

    2 countries

  • Planned duration10/10

    Planned over about 64 months

  • Sponsor scale9/10

    AbbVie has led 364 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (aged 6-17 years) with a history of migraine will be enrolled. The study will include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort). Participants aged 6-11 years in the PK Cohort will receive Dose A or Dose B of Ubrogepant for PK analysis to determine dose selection for the main study. In the main study, after dose selection, children aged 6-11 years will be randomized to receive either low or high dose of Ubrogepant or placebo. There is a 1 in 3 chance that a participant will be assigned to placebo. Adolescents aged 12-17 years will be randomized to receive either low or high dose of Ubrogepant or placebo with a 1 in 3 chance of placebo assignment. For qualifying migraine attacks, participants will receive oral tablets of the double-blind study intervention. There will be an option to take a second dose of double-blind study intervention (identical to initial dose), or rescue medication, at least 2 hours after the initial dose, for headache of moderate/severe intensity. Around 1059 participants will be enrolled in the study in approximately 120 sites in the United States. The study duration will be up to 6 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Patologie

  • Migraine

Idoneità

SessoTutti
Età6 Years – 17 Years
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: * A history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD-3) for at least 6 months. * By history, the participant's migraines typically last between 3 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom. * History of 1 to 14 migraine attacks per month with moderate to severe headache in each of the 2 months prior to screening (Visit 1). * Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the acute treatment of migraine. * For main study participants, treatment of a qualifying migraine with single-blind placebo during the screening period and completion of 2-hour headache pain assessment. * Weight is ≥ 20 kg (44 pounds) and \< 135 kg (298 pounds) * Per investigator judgment, participant is able to swallow or can learn to swallow study intervention. * The participant is able to understand and complete the study questionnaires and eDiary. Participants who need assistance with reading the assessments may be assisted by a parent or guardian. Exclusion Criteria: * Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular or neurologic disease. * In the opinion of the investigator, other confounding pain syndromes, confounding psychiatric conditions, or other significant neurological disorders other than migraine. * History of malignancy in the 5 years prior to Visit 1. * History of any prior gastrointestinal conditions (eg, diarrhea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of the study intervention. * Significant risk of self-harm, based on clinical interview and responses on the Columbia-Suicide Severity Rating Scale (C-SSRS), or of harm to others; participants must be excluded if they report suicidal ideation with intent, with or without a plan, (ie, Type 4 or 5 on the C-SSRS) in the past 6 months or report suicidal behavior in the last 6 months prior to Visit 1 or Visit 2 assessments. * At Visit 1, current alcohol or drug abuse or dependence per investigator's judgment. * For main study participants, no headache at the 2-hour post dose assessment after taking single-blind placebo for a qualifying migraine during screening period (ie, placebo responder). * A current diagnosis of chronic migraine as defined by ICHD-3 * Participants who overuse medication for migraine defined as use of opioids or barbiturates \> 2 days/month, triptans or ergots ≥ 10 days/month, simple analgesics (eg, aspirin, NSAIDs, acetaminophen) ≥ 15 days/month or any combination of triptans, ergots, or simple analgesics (eg, aspirin, NSAIDs, acetaminophen) ≥ 10 days/month in the 3 months prior to Visit 1 per investigator's judgment. * Difficulty distinguishing migraine headache from tension-type or other headaches. * Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine as defined by ICHD-3. * Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3 * Required in-hospital (excluding emergency department visits) treatment for migraines 3 or more times in the 6 months prior to Visit 1. * Requirement for any medication (eg, barbiturates) or diet (eg, grapefruit juice) that is on the list of prohibited concomitant medications that cannot be discontinued or switched to an allowable, alternative medication at Visit 1. * Previous exposure, within the last 6 months, to injectable monoclonal antibodies blocking the calcitonin gene-related peptide (CGRP) pathway * History of hypersensitivity or clinically significant adverse reaction to a CGRP receptor antagonist or hypersensitivity to any component of the study interventions, ubrogepant or placebo. * Currently participating or has participated in a study with an investigational compound or device within 30 days prior to Visit 1

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Tipo di studioInterventistico
FaseFase 3
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoTRIPLE (3)
Arruolamento1059 partecipanti ricercati

Sponsor e collaboratori

  • AbbVie Sponsor

Bracci e interventi

  • PK Cohort: Ubrogepant Dose AEXPERIMENTAL

    Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.

  • PK Cohort: Ubrogepant Dose BEXPERIMENTAL

    Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.

  • Main Study: Children Ubrogepant Low DoseEXPERIMENTAL

    Participants aged 6 to 11 (after dose selection) will receive oral tablets of low dose ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

  • Main Study: Children Ubrogepant High DoseEXPERIMENTAL

    Participants aged 6 to 11 (after dose selection) will receive oral tablets of high dose ubrogepant Dose B for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

  • Main Study: Children Ubrogepant PlaceboPLACEBO_COMPARATOR

    Participants aged 6 to 11 (after dose selection) will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

  • Main Study: Adolescents Ubrogepant Low DoseEXPERIMENTAL

    Participants aged 12 to 17 will receive oral tablets of ubrogepant low dose for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

  • Main Study: Adolescents Ubrogepant High DoseEXPERIMENTAL

    Participants aged 12 to 17 will receive oral tablets of ubrogepant high dose or qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

  • Main Study: Adolescents Ubrogepant PlaceboPLACEBO_COMPARATOR

    Participants aged 12 to 17 will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

Interventi

  • Farmaco Placebo-Matching Ubrogepant

    Oral Tablet

  • Farmaco Ubrogepant

    Oral Tablet

Esiti misurati

  1. Esito primario

    Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years

    Pain Freedom is defined as a reduction in headache severity from moderate/severe at baseline to no pain.

    Orizzonte temporale 2 hours after initial dose

  2. Esito secondario

    Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 12 to 17 years

    Pain Freedom is defined as a reduction in headache severity from moderate/severe at baseline to

    Orizzonte temporale 2 hours after initial dose

  3. Esito secondario

    Percentage of participants with Pain Relief at 2 Hours After the Initial Dose in pediatric participants aged 12 to 17 years

    Pain Relief is defined as a reduction in headache severity from moderate/severe at baseline to mild or no pain.

    Orizzonte temporale 2 hours after initial dose

  4. Esito secondario

    Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose in pediatric participants aged 6 to 17 years

    Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug.

    Orizzonte temporale 2 to 24 hours after initial dose

  5. Esito secondario

    Percentage of participants that used rescue medication (including a second dose of study intervention) within 24 hours after the initial dose in pediatric participants aged 6 to 17 years

    Orizzonte temporale 24 hours after initial dose

  6. Esito secondario

    Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose in pediatric participants aged 6 to 17 years

    The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'.

    Orizzonte temporale Baseline (Predose) to 2 hours after initial dose

  7. Esito secondario

    Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose in pediatric participants aged 12 to 17 years

    The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'.

    Orizzonte temporale Baseline (Predose) to 2 hours after initial dose

  8. Esito secondario

    Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 6 to 11 years

    Pain Freedom is defined as a reduction in headache severity from moderate/severe at baseline to no pain.

    Orizzonte temporale 2 hours after initial dose

  9. Esito secondario

    Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years

    Photophobia was defined as sensitivity to light, a migraine-associated symptom.

    Orizzonte temporale 2 hours after initial dose

  10. Esito secondario

    Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years

    Phonophobia was defined as sensitivity to sound, a migraine-associated symptom.

    Orizzonte temporale 2 hours after initial dose

  11. Esito secondario

    Percentage of Participants With the Absence of Nausea at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years

    Nausea was a migraine-associated symptom.

    Orizzonte temporale 2 hours after initial dose

  12. Esito secondario

    Number of Participants with Adverse Events (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Orizzonte temporale Up to 6 months

  13. Esito secondario

    Percentage of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed in pediatric participants aged 6 to 17 years

    Percentage of participants with abnormal change in clinical laboratory test results like hematology will be assessed.

    Orizzonte temporale Up to 6 months

  14. Esito secondario

    Change From Baseline in Electrocardiograms (ECGs) in pediatric participants aged 6 to 17 years

    12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF).

    Orizzonte temporale Up to 6 months

  15. Esito secondario

    Percentage of Participants with Abnormal Change From Baseline in Vital Sign Measurements in pediatric participants aged 6 to 17 years

    Percentage of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

    Orizzonte temporale Up to 6 months

  16. Esito secondario

    Percentage of patients with suicidal ideation or suicidal behavior

    Orizzonte temporale Up to 6 months

Date

Data di inizio13 gennaio 2022 (effettiva)
Conclusione primaria1 maggio 2027 (stimata)
Conclusione1 maggio 2027 (stimata)
Prima pubblicazione18 novembre 2021 (effettiva)
Ultimo aggiornamento14 settembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltasettembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

91 centri stanno reclutando

Puerto Rico

StrutturaCittàStato o regioneStato
Clinical Research Investigator Group /ID# 267454BayamónCompletato
Puerto Rico Health Institute /ID# 249162DoradoIn reclutamento
GCM Medical Group /ID# 249643San JuanIn reclutamento
Caribbean Medical Research Center Headlands /ID# 265301San JuanIn reclutamento

United States

StrutturaCittàStato o regioneStato
Accellacare - McFarland Clinic /ID# 229789AmesIowaIn reclutamento
Dent Neurologic Institute - Amherst /ID# 231182AmherstNew YorkIn reclutamento
Advanced Research Center /ID# 227962AnaheimCaliforniaIn reclutamento
Hunterdon Neurology /ID# 245648AnnandaleNew JerseyCompletato
Treken Primary Care /ID# 240586AtlantaGeorgiaCompletato
Clinical Integrative Research Center of Atlanta (CIRCA) /ID# 231134AtlantaGeorgiaIn reclutamento
Rare Disease Research /ID# 231046AtlantaGeorgiaIn reclutamento
Children's Hospital Colorado - Aurora /ID# 231879AuroraColoradoIn reclutamento
Paradigm Clinical Research - Aurora, CO /ID# 280612AuroraColoradoIn reclutamento
Austin Regional Clinic - ARC Four Points /ID# 276301AustinTexasIn reclutamento
UT Health Austin at Dell Children's Neurology Clinic /ID# 244266AustinTexasIn reclutamento
BioBehavioral Research of Austin /ID# 230529AustinTexasCompletato
Velocity Clinical Research, Austin /ID# 230557AustinTexasIn reclutamento
Pharmasite Research, Inc. /ID# 227908BaltimoreMarylandIn reclutamento
Tekton Research - Beaumont /ID# 231207BeaumontTexasCompletato
Pantheon Clinical Research /ID# 250703BountifulUtahIn reclutamento
Encore Medical Research of Boynton Beach LLC /ID# 246833Boynton BeachFloridaIn reclutamento
Coastal Georgia Child Neurology /ID# 231409BrunswickGeorgiaIn reclutamento
Minneapolis Clinic of Neurology - Burnsville /ID# 232551BurnsvilleMinnesotaIn reclutamento
IMMUNOe Research Centers /ID# 230879CentennialColoradoCompletato
Coastal Pediatric Research /ID# 238616CharlestonSouth CarolinaCompletato
Onsite Clinical Solutions - Don Lochman Lane - Charlotte /ID# 282834CharlotteNorth CarolinaIn reclutamento
CVS HealthHUB - Charlotte /ID# 239530CharlotteNorth CarolinaCompletato
Pediatric Associates of Charlottesville, PLC /ID# 230628CharlottesvilleVirginiaIn reclutamento
Chicago Headache Center & Research Institute /ID# 248625ChicagoIllinoisIn reclutamento
Headache Center of Hope /ID# 242645CincinnatiOhioIn reclutamento
Cincinnati Childrens Hospital Medical Center /ID# 244689CincinnatiOhioIn reclutamento
University Of Cincinnati Medical Center /ID# 231199CincinnatiOhioIn reclutamento
Patient Priority Clinical Sites, LLC /ID# 238485CincinnatiOhioIn reclutamento
MCB Clinical Research Centers - Colorado Springs - South Parkside Drive /ID# 231625Colorado SpringsColoradoCompletato
Centricity Research Columbus /ID# 231181ColumbusOhioIn reclutamento
Relaro Medical Trials /ID# 239642DallasTexasIn reclutamento
Cedar Health Research /ID# 228003DallasTexasIn reclutamento
Epic Medical Research - DeSoto /ID# 274314DeSotoTexasIn reclutamento
CenExcel iResearch LLC /ID# 227903DecaturGeorgiaCompletato
3A Research - East El Paso /ID# 239193El PasoTexasCompletato
Core Clinical Research /ID# 227904EverettWashingtonIn reclutamento
Gulf Coast Clinical Research Center /ID# 230020Fort MyersFloridaIn reclutamento
Office of Maria Ona /ID# 234232FranklinVirginiaCompletato
Neuro Pain Research Center /ID# 227966FresnoCaliforniaIn reclutamento
Earle Research /ID# 231548FriendswoodTexasCompletato
Innovare Research Group, LLC /ID# 277617FriendswoodTexasIn reclutamento
Sarkis Clinical Trials /ID# 227956GainesvilleFloridaCompletato
HealthStar Research Glenwood /ID# 275303GlenwoodArkansasIn reclutamento
Tribe Clinical Research LLC /ID# 230422GreenvilleSouth CarolinaIn reclutamento
Duplicate_Premier Neurology, P.C. /ID# 227999GreerSouth CarolinaCompletato

Nella scheda del registro sono indicati altri 79 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 14 settembre 2026

    Centro aggiunto

    1 site added (129 total)

    128129

  2. 8 settembre 2026

    Centro aggiunto

    1 site added (128 total)

    127128

  3. 1 settembre 2026

    Centro aggiunto

    1 site added (127 total)

    126127

  4. 24 agosto 2026

    Centro aggiunto

    1 site added (126 total)

    125126

  5. 21 agosto 2026

    Centro rimosso

    4 sites removed (125 total)

    129125

Registro: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT05125302